Prosecution Insights
Last updated: November 20, 2026

Caralynne E Helm, USPTO Patent Examiner

Listed by the USPTO as HELM, CARALYNNE E

Tech Center 1600 • Art Units: 1615

This examiner grants 29% of resolved cases

Analysis

HELM, CARALYNNE E examines in Tech Center 1600 and Art Unit 1615. Her record includes 805 resolved cases, with a 28.9% allowance rate. Interview lift is 49.9%, a substantial reported association relative to the underlying allowance result, so interview preparation may be important when a case is positioned for reconsideration.

The median time to allowance is 1497 days, indicating a lengthy path in the reported record. Practitioners may need to plan for sustained prosecution and preserve clear claim distinctions through multiple response stages. The leading companies are Spiral Therapeutics Inc., L'Oréal, and Nestlé S.A. The principal firms are FISH & RICHARDSON P.C. (TC), K&L Gates LLP-Nestec S.A., and Apex Attorneys at Law, LLP.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

28.9%
Allow Rate
-31.1% vs TC avg
880
Total Applications
+49.9%
Interview Lift
1497
Avg Prosecution Days
Based on 805 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
8.6%
§102 Novelty
44.1%
§103 Obviousness
29.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19530028 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR Final Rejection Spiral Therapeutics, Inc.
19463990 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR Non-Final OA Spiral Therapeutics, Inc.
19459988 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR Final Rejection Spiral Therapeutics Inc.
17923945 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR Non-Final OA Spiral Therapeutics Inc.
18423951 SURGICAL SYSTEM AND METHODS OF USE Non-Final OA Medtronic, Inc.
18678709 MARIBAVIR COMPOSITIONS AND USES THEREOF Non-Final OA Takeda Pharmaceutical Company Limited
18254312 RAPIDLY RESORBABLE INTRAVASCULAR IMPLANT Non-Final OA BIOTRONIK AG
19374982 ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS Non-Final OA Jazz Pharmaceuticals Research UK Limited
17740607 COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
17595159 COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
18029619 METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPLANT ASSOCIATED COMPLICATIONS Final Rejection The Board of Trustees of the Leland Stanford Junior University
19195301 HARD SURFACE CLEANING SOLUTION WITH RAPID VIRICIDAL ACTIVITY Non-Final OA ECOLAB USA INC.
17556093 DUAL AGENT NANOPARTICLE COMPOSITION FOR COATING MEDICAL DEVICES Non-Final OA THE CLEVELAND CLINIC FOUNDATION
18918858 METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLE Non-Final OA DSM IP Assets B.V.
18877255 STABILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME Non-Final OA L'OREAL
18602424 PROCESS FOR COLOURING A BASE COSMETIC COMPOSITION Final Rejection L'Oreal
18580525 COMPOSITION COMPRISING A SPECIFIC COMBINATION OF SURFACTANTS AND A CATIONIC POLYMER Non-Final OA L'Oreal
18543756 COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND AVOBENZONE Final Rejection L'OREAL
18688413 BIOACTIVE GLASS COMPOSITIONS AND METHODS OF TREATMENT Final Rejection The Curators of the University of Missouri
17629639 WATER BASED COMPOSITION Final Rejection Shiseido Company, Ltd.
18700520 COMPOSITIONS FOR DELIVERY OF CANNABINOIDS Non-Final OA PNEUMA RESPIRATORY, INC.
18091615 OPTICALLY CLEAR, IN-SITU FORMING BIODEGRADABLE NANO-CARRIERS FOR OCULAR THERAPY, AND METHODS USING SAME Final Rejection Rowan University
17392361 REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESS Final Rejection MannKind Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Caralynne E Helm's allowance rate?

28.9% of resolved applications examined by Caralynne E Helm were allowed (805 resolved cases), compared with 43.8% across Art Unit 1615 over the last five years.

Does an interview help with examiner Caralynne E Helm?

This examiner's interview lift is +49.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Caralynne E Helm take to allow a patent?

Applications allowed by Caralynne E Helm took 1,497 days on average from filing to allowance.

Which art unit does examiner Caralynne E Helm work in?

Caralynne E Helm examines applications in Art Unit 1615 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month